Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-BLyS antibody

一种抗体、序列的技术，应用在抗体、抗体医疗成分、抗炎剂等方向，能够解决毒性强、疗效差、特异性差等问题

Active Publication Date: 2013-12-04
WUHAN THERASOURCE BIOSCI +1
View PDF1 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with Benlysta, they have poor specificity, weak binding, relatively poor efficacy and strong toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-BLyS antibody
  • Anti-BLyS antibody
  • Anti-BLyS antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1: Cloning and expression of human BLyS gene

[0063] Peripheral blood of healthy people was isolated, and total RNA was extracted and purified with a commercial RNA kit (Qiagen). Using purified total RNA as a template, reverse transcription to synthesize cDNA first-strand cDNA. The reaction system is as follows:

[0064]

[0065] Add sterilized distilled water to make up the total amount of the system 20 μL.

[0066] The reaction conditions were: 30°C for 10 minutes, 42°C for 30 minutes, 99°C for 5 minutes, and 4°C for 5 minutes. After the reaction was completed, ice bath for 5 min.

[0067] According to the full-length DNA sequence of human BLyS, the cloned secreted BLyS primers P1 and P2 were designed and synthesized, and the cDNA synthesized by reverse transcription was used as the template to carry out PCR amplification with the upstream primer P1 and the downstream primer P2. The nucleotide sequences of P1 and P2 are as follows:

[0068] P1: 5'tacga...

Embodiment 2

[0077] Example 2: Detection of the ability to bind to receptors on BJAB cells

[0078] 1. Biotin-labeled his-hBLyS recombinant protein

[0079] The his-hBLyS recombinant protein purified in Example 1 was mixed with biotin-xx-NHS dissolved in DMSO at a weight-to-volume ratio of 1:4 in ng / mL, placed at room temperature for 1 hour, and the reaction mixture was passed through a gel column , separation of biotin-labeled his-hBLyS and free biotin.

[0080] 2. Biotin-labeled his-hBLyS recombinant protein combined with BJAB cells

[0081] The isolated biotin-labeled his-hBLyS recombinant protein was divided into four different concentration groups, 25ng / mL, 50ng / mL, 100ng / mL and 200ng / mL, respectively with 1×10 6 The Burkitt's lymphoma cells (BJAB) cells were mixed, incubated at 4°C for 15 minutes, washed 3 times with PBS, added with straptavidin allophycocyanin (SA-APC) to a final concentration of 0.2 μg / mL, and incubated at 4°C for 20 minutes. After washing 3 times with PBS, the ...

Embodiment 3

[0083] Example 3: Immunization of mice

[0084] The his-hBLyS recombinant protein purified in Example 1 was mixed with an equal amount of immune adjuvant (Freund's adjuvant) as an antigen, and 4 6-week-old female FVB mice were taken, 3 of which were immunized and the other was subjected to control simulation. experiment. After the primary immunization, booster immunizations were performed once a week. Before the last booster immunization, blood was drawn from the hearts of immunized mice, and their serum was mixed with biotin-labeled his-hBLyS recombinant protein (concentration 50ng / mL) and incubated at room temperature for 20 minutes. The mixture was then incubated with BJAB cells at 4°C for 15 minutes, and after 3 washes with physiological saline, 0.2 μg / mL of straptavidin allophycocyanin was added and incubated at 4°C for 15 minutes. After eluting with normal saline for 3 times, the samples were flow cytometer to detect whether the serum of the immunized mice could inhibi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-FC thereof. Also provided are uses of the anti-BLyS antibody in the preparation of drugs for preventing and / or treating diseases such as systemic lupus erythematosus caused by the excessive proliferation of B cells.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to an anti-BLyS antibody and application thereof. The anti-BLyS antibody can combine with a B lymphocyte stimulating factor and can inhibit the combination of the B lymphocyte stimulating factor and its receptor BR3-Fc. It further relates to a humanized anti-BLyS antibody with low affinity to MHC II factor and application thereof. Background technique [0002] Systemic lupus erythematosus (SLE) is a chronic and progressive autoimmune disease involving multiple systems of the body, such as the skin, joints, heart, lungs, kidneys, blood and brain, often in remission and relapse disease. Systemic lupus erythematosus primarily affects people of African-Caribbean, Asian, and Hispanic descent, and to a lesser extent Caucasian (white) people. According to the Lupus Foundation of America, it is conservatively estimated that systemic lupus erythematosus affects 300,000 people in the United States. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24C12N15/13C12N15/63C12N1/21C12N1/19C12N1/15C12N5/10A61K39/395A61P29/00A61P19/02A61P35/00A61P37/02
CPCA61K39/395C07K16/24C07K16/2875A61K2039/505A61P19/02A61P29/00A61P35/00A61P37/02A61P37/06C07K16/241C12N15/63A61K39/3955C12N5/10C12N5/12C12N15/09C07K2317/73C12P21/02C07K2317/14C07K2317/24C07K2317/52C07K2317/56C07K2317/565C07K2317/76
Inventor 陈博舒红兵
Owner WUHAN THERASOURCE BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com